Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
Authors White DE, Zhao Y, Ogundele A, Fulcher N, Acs A, Moore-Schiltz L, Karpecki PM
Received 6 August 2019
Accepted for publication 31 October 2019
Published 22 November 2019 Volume 2019:13 Pages 2285—2292
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Darrell E White,1 Yang Zhao,2 Abayomi Ogundele,2 Nicole Fulcher,3 Annabel Acs,3 Laura Moore-Schiltz,3 Paul M Karpecki4
1Department of Ophthalmology, SkyVision Centers, Westlake, OH 44145, USA; 2Health Economics and Outcomes Research, Sun Pharmaceutical Industries, Princeton, NJ 08540, USA; 3Outcomes Research, IBM Watson Health, Cambridge, MA 02142, USA; 4Corneal Services and Advanced OSD Clinic, University of Pikeville Kentucky College of Optometry, Pikeville, KY 41501, USA
Correspondence: Yang Zhao
Health Economics and Outcomes Research, Sun Pharmaceutical Industries, Inc., 2 Independence Way, Princeton, NJ 08540, USA
Tel +1 609 720 8132
Purpose: To assess adherence, non-persistence, discontinuation, and switching of topical cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast ophthalmic solution 5% (LIF) use in the real world among patients with dry eye disease (DED).
Design: Retrospective insurance claims study.
Methods: Adult patients with DED and ≥1 prescription claim for CYC or LIF (first claim = index date) in the IBM® MarketScan® databases from July 2016 to February 2018 were identified. Eligible patients had continuous medical and pharmacy benefits in the 12 months pre- and post-index periods, and no prior use of the index medication. The proportion of days covered (PDC), adherence, non-persistence, discontinuation, and switching were examined over the 12-month post-index period.
Results: This study included 6537 CYC and 3235 LIF patients. The adherence rate was 5.9% for CYC and 9.7% for LIF; the median PDC was 0.3 for both cohorts. Overall, 70.8% of CYC and 64.4% of LIF patients discontinued treatment with median days to discontinuation of 89 and 29, respectively. Non-persistence was 7.1% for CYC and 6.8% for LIF (median days to discontinuation: 89 and 105). In addition, 5.0% switched from CYC to LIF, and 9.6% switched from LIF to CYC over the post-index period.
Conclusion: Over 60% of DED patients discontinued treatment within 12 months of initiation; the median time to discontinuation was 3 months for CYC and 1 month for LIF. Although this analysis did not capture the reasons why patients discontinued treatment, the results demonstrate there likely exists a significant unmet need amongst DED patients.
Keywords: dry eye disease, adherence, persistence, cyclosporine ophthalmic emulsion, lifitegrast ophthalmic solution
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]